NKGN

100.00% -0.1325

アフターアワーズ： .13 0.13 +

Nkgen Biotech Inc (NKGN)

概要ニュース株価時系列なぜNKGNが下落しているのか？ディスカッション予測

Relative Volume:

ネットキャッシュフロー:

Nkgen Biotech Inc Stock (NKGN) Company Profile

Nkgen Biotech Inc

Healthcare (1145)

Biotechnology (641)

NKGN's Discussions on Twitter

NKGN を他の銘柄と比較する

株式	価格	時価総額	収益	当期純利益	現金流量	EPS
NKGN Nkgen Biotech Inc	0.00	0	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	391.02	100.52B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	580.70	61.43B	14.21B	4.46B	3.56B	39.68
ALNY Alnylam Pharmaceuticals Inc	446.51	59.29B	2.46B	-319.09M	-52.09M	-2.47
ARGX Argen X Se Adr	712.20	43.09B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	306.05	35.42B	3.81B	-644.79M	-669.77M	-6.24

Nkgen Biotech Inc (NKGN) 最新ニュース

Nkgen Biotech Inc (NKGN) 財務データ

Nkgen Biotech Inc (NKGN) の財務データはありません。詳細については、他の銘柄を確認してください。

Nkgen Biotech Inc (NKGN)

Nkgen Biotech Inc Stock (NKGN) Company Profile

NKGN を他の銘柄と比較する

Nkgen Biotech Inc (NKGN) 最新ニュース

Alzheimer's Disease Pipeline 2025: Detailed Clinical Trials And FDA-Approved Therapies Review By Delveinsight Neurodon, Sangamo Therapeutics, Nkgen Biotech, Asceneuron, Truebinding, Alector - MenaFN

NKGen Biotech, Inc. (NYSE:NKGN) Short Interest Update - Defense World

NKGen Biotech To Present on Allogeneic Enhanced NK Cells - GlobeNewswire

Breakthrough: NKGen's NK Cell Cancer Therapy Eliminates Need for Harsh Pre-Treatment in Solid Tumors - Stock Titan

Critical Contrast: NKGen Biotech (NYSE:NKGN) & Cortexyme (NASDAQ:CRTX) - Defense World

NKGen Biotech Presents Troculeucel Mechanism of Action with - GlobeNewswire

Revolutionary NK Cell Therapy Transforms Moderate Alzheimer's to Mild Stage in Clinical Trial - Stock Titan

NKGen Biotech to Present at the Alzheimer’s Association International Conference 2025 - GlobeNewswire

Revolutionary NK Cell Therapy Shows Promise in Alzheimer's Disease: Phase 1 Data Reveal Key Insights - Stock Titan

NKGen Biotech Gets FDA Expanded Access - Orange County Business Journal

NKGen Secures FDA Expanded Access For NK Cell Therapy In Neurodegenerative Diseases, Stock Down - Nasdaq

FDA grants expanded access for NKGen’s cell therapy in neurodegenerative diseases By Investing.com - Investing.com South Africa

FDA grants expanded access for NKGen’s cell therapy in neurodegenerative diseases - Investing.com Nigeria

NKGen Receives FDA Expanded Access Protocol Authorization for Landmark Treatment of Several Neurodegenerative Diseases - The Manila Times

NKGen Receives FDA Expanded Access Protocol Authorization - GlobeNewswire

FDA Grants Breakthrough Access: NKGen's NK Cell Therapy Now Available for Multiple Untreatable Brain Diseases - Stock Titan

NKGen Biotech and HekaBio enter strategic partnership to bring novel NK cell therapy to Japan - BioSpectrum Asia

NKGen and HekaBio partner to advance NK cell therapy in Japan - Investing.com India

NKGen Biotech Partners with HekaBio for SNK01 in Japan - TipRanks

NKGen and HekaBio partner to advance NK cell therapy in Japan By Investing.com - Investing.com South Africa

NKGen Biotech and HekaBio Enter Strategic Partnership to Bring Novel NK Cell Therapy to Japan - GlobeNewswire

Vivos Therapeutics shares rise 1.81% premarket after NKGen Biotech's new funding announcement. - AInvest

NKGen Biotech Announces New Funding to Regain Compliance with Reporting Obligations and Listing Standards - GlobeNewswire

NKGen Biotech (NYSE:NKGN) versus CEL-SCI (NYSE:CVM) Head-To-Head Comparison - Defense World

Nasdaq Announces Delisting of Multiple Companies Including NKGen Biotech, Aquaron Acquisition Corp, and Others - Quiver Quantitative

Delisting of Securities from The Nasdaq Stock Market - Yahoo Finance

NKGen Biotech (NYSE:NKGN) Stock Price Down 0.2% – What’s Next? - Defense World

NKGen administers first dose of NK cell therapy to Alzheimer’s patient - Investing.com Australia

NKGen administers first dose of NK cell therapy to Alzheimer’s patient By Investing.com - Investing.com South Africa

NKGen Biotech Administers First Dose of Troculeucel to - GlobeNewswire

Breakthrough: New NK Cell Treatment Offers Hope for Alzheimer's Patients Who Failed Standard Therapy - Stock Titan

NKGen activates new sites for Phase I/IIa study of Alzheimer’s cell therapy - yahoo.com

Revolutionary NK Cell Therapy for Alzheimer's Expands Clinical Trial to International Sites - Stock Titan

NKGen Biotech Approved as Preferred Bidder for NKMAX - TipRanks

NKGN gets stakeholder nod for NKMAX takeover; closing slated Aug 2025 | NKGNW SEC FilingForm 8-K - Stock Titan

NKMAX completes sale to NKGen, eyes delisting prevention and future recoveryCHOSUNBIZ - Chosunbiz

Nkgen biotech sees $2.5 million stock purchase by major shareholder - Investing.com Canada

NKGen Biotech Enters Stock Purchase Agreement - TipRanks

NKGen Biotech Delays Quarterly Report Filing - TipRanks

NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally - GlobeNewswire

NKGen Biotech’s Strategic Stock Purchase Agreement - TipRanks

NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally Invests $2.65 Million Cash to Accelerate Phase 2 Clinical Trial and Fulfill Financial Reporting Obligations - Stock Titan

NKGen Biotech to Present Phase 1 Clinical Data on Troculeucel for Alzheimer's Disease at ASGCT Annual Meeting - Nasdaq

NKGen Biotech to Present Troculeucel Clinical and Biomarker - GlobeNewswire

NKGen Biotech to Present Troculeucel Clinical and Biomarker Results at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting - Stock Titan

Head-To-Head Review: NKGen Biotech (NYSE:NKGN) and Athira Pharma (NASDAQ:ATHA) - Defense World

NKGen Biotech secures amended loan terms with East West Bank By Investing.com - Investing.com India

NKGen Biotech secures amended loan terms with East West Bank - Investing.com

Nkgen Biotech Inc (NKGN) 財務データ

収益

当期純利益

現金流量

EPS

NKGNに似た銘柄